ClearPoint Neuro, Inc. announced that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro’s Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc., is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuro’s Board as PTC’s representative in connection with PTC’s May 2019 equity investment in ClearPoint Neuro. Mr. Souza, who resigned from his position as PTC’s Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuro’s Board as an independent member. Prior to joining PTC, Dr. Klein served in several executive positions with BioElectron Technology Corporation, most recently as BioElectron’s Chief Executive Officer and a Director prior to its acquisition by PTC in 2019.